China Electronics Health Data and WuXi AppTec Establish Joint Venture Zhongdian PharmData to Advance Healthcare Big Data Industry

On October 23, VCBeat (WeChat official account: vcbeat) learned that CEC Data and WuXi AppTec announced today the establishment of a joint venture, CEC-WuXi, to jointly delve into the healthcare big data industry. Leveraging clinical diagnosis and prescription data, the two parties will provide healthcare data solutions to pharmaceutical companies, biotechnology firms, insurance companies, government agencies, research institutions, and other life sciences organizations, thereby further promoting innovative development in the medical industry and benefiting more patients in China.

CEC WuXi leverages the National Health and Medical Big Data Service Platform and the National Health and Medical Big Data Security Platform, established by China Electronics Data, to integrate WuXi AppTec’s professional expertise and extensive experience in new drug development and the broader health industry. While strictly adhering to national laws and regulations on health and medical big data security management and ensuring multi-dimensional data protection, CEC WuXi employs internationally leading technologies for data collection, mining, and analytical processing. It provides partners with comprehensive, integrated health and medical big data analytics products and solutions covering the entire industry chain—from drug development and post-market efficacy evaluation to distribution and sales. CEC WuXi is committed to helping partners gain deep insights into the needs of Chinese patients, accelerating the market entry of urgently needed new therapies, and striving to become a leader in China’s health and medical big data sector.

“The establishment of CEC WuXi represents a significant strategic move by CEC Data in the field of healthcare big data analytics. Healthcare big data is a critical foundational strategic resource for the nation, and its application and development will bring about profound changes to healthcare models. WuXi AppTec is a leading open-access capability and technology platform in the global biopharmaceutical industry, and we are highly optimistic about this collaboration with WuXi AppTec. In the future, we will comprehensively leverage technologies such as big data, cloud computing, and artificial intelligence to achieve deep integration of hospital, insurance, clinical, epidemiological, and prescription data with R&D resources. This will enable us to provide core data solutions to both international and local partners in China, thereby effectively realizing CEC Data’s vision of promoting greater health and happiness for the people,” stated Li Shifeng, Chairman of CEC Data.

“This collaboration marks a significant step for WuXi AppTec in deepening its engagement with the medical big data industry. It will help us efficiently integrate clinical diagnosis and treatment data with pharmaceutical R&D resources, providing more comprehensive and effective solutions for the broader health ecosystem,” said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. “Through this partnership, we aim to uncover more precise patient needs and derive deeper insights from healthcare data, thereby empowering more physicians, scientists, and healthcare companies. Our goal is to enable doctors to deliver better care and patients to receive superior treatment, accelerating the realization of our vision: ‘to make it easy to develop drugs and cure diseases.’”

“As an expert with over 20 years of experience in the healthcare industry, Liu Anting, CEO of CEC WuXi, stated: ‘CEC WuXi will become a highly distinctive joint venture. By leveraging the combined strengths of CEC Data and WuXi AppTec, CEC WuXi will assume a leadership position in the field of big data analytics for healthcare, driving further development across the entire healthcare sector and ultimately delivering benefits to patients worldwide. We look forward to collaborating closely with other companies specializing in healthcare big data, artificial intelligence, and software to jointly build a better future.’”

China Electronics Data Service Co., Ltd. (hereinafter referred to as “CEC Data”) is the national team for the development of the health and medical big data industry, established under the guidance of the National Health Commission and led by China Electronics Corporation (CEC). CEC Data is recognized as a National High-Tech Enterprise and a Zhongguancun High-Tech Enterprise. Adhering to the principle of “security first, data services, platform operations, and ecosystem development,” the company focuses on building two core capabilities: “security” and “intelligence.” Leveraging its affiliation with the national cybersecurity and informatization champion, China Electronics Corporation, CEC Data has constructed a comprehensive security system covering the entire data lifecycle, based on intrinsic security, process security, industrial control security, and data security. It possesses an integrated security platform comprising three components: a security convergence system, a security management and control system, and a security emergency response system.CEC Data serves as the primary entity responsible for the construction and operation of the National Health and Medical Big Data Pilot Project (Fuzhou). It is the sole implementing entity for the national “Internet + Healthcare” major project, a co-builder of the National Engineering Laboratory for Applied Technologies in Medical Big Data, and the secretariat unit of the Professional Committee on Health and Medical Big Data Industry Development and Information Security of the Chinese Health Information Association (also known as the China Health and Medical Big Data Industry Alliance). As a key initiator, CEC Data jointly invested with Shanghai State-owned Capital Investment Group and others to establish the Shanghai Data Exchange. Furthermore, CEC Data initiated the establishment of the CEC Health Industry Fund and its management company, CEC Shurong Investment Management Co., Ltd., to build a robust ecosystem for health and medical big data.

WuXi AppTec (Stock Code: 603259) is an internationally leading open-access capability and technology platform company, providing comprehensive, integrated laboratory R&D and manufacturing services—from drug discovery and development to commercialization—for the global pharmaceutical and medical device industries. Adhering to its mission of prioritizing research and centering on customers, WuXi AppTec helps global clients shorten R&D cycles and reduce costs for drugs and medical devices through a cost-effective and highly efficient service platform. The company’s platform encompasses small-molecule drug R&D and manufacturing, cell and gene therapy R&D and manufacturing, and medical device testing, among others. It currently supports thousands of R&D innovation projects for more than 3,000 innovative partners across over 30 countries, committed to delivering the latest and best pharmaceutical and healthcare products to patients worldwide, thereby realizing its vision of “making it easy to develop drugs and treat difficult diseases.”